Article Text

Download PDFPDF
Adalimumab: a new modality for Behçet’s disease?
  1. J A M van Laar,
  2. T Missotten,
  3. P L A van Daele,
  4. A Jamnitski,
  5. G S Baarsma,
  6. P M van Hagen
  1. Erasmus University Medical Center, Rotterdam, The Netherlands
  1. Correspondence to:
    Dr J A M van Laar
    Room D-419, Erasmus University Medical Center, Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands; j.vanlaar{at}

Statistics from

Aberrant T cell function,1 subsequently accompanied by increased tumour necrosis factor α (TNFα) levels, induces inflammatory symptoms in patients with Behçet’s disease (BD).2 Subsequently, treatment usually involves T cell-directed immunosuppressive or anti-TNFα treatment in patients with severe disease.3–7 Administration of the new human monoclonal TNFα antibody adalimumab has only been described in three patients with BD with uveitis.8 We analysed the effects of adalimumab on severe and often chronic disease in six heavily pretreated patients with BD in whom immunosuppressive therapy had failed (table 1).

View this table:
Table 1

 Clinical effects in patients treated with infliximab or adalimumab for Behçet’s disease

These patients were treated in the past with infliximab.9 Indications for anti-TNFα treatment …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.